VIDEO: ‘Compelling’ data on MDM2 inhibitor for liposarcoma

BySavannah Demko

Fact checked byMindy Valcarcel, MS

Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of BI-907828, a MDM2 inhibitor, in patients with liposarcoma presented at the Connective Tissue Oncology Society Annual Meeting.

“These data are compelling and interesting, particularly in the context of a recent, different MDM2-inhibitor, which the study did not meet primary endpoint,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, told Healio in a video interview.

Reference:

Schöffski P, et al. Paper 23. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.

Take Homes from CTOS Annual Meeting

Read more

VIDEO: ‘Compelling’ data on MDM2 inhibitor for liposarcoma

Reference:

Related Content